Similar articles

• Money and distorted ethical judgments about research: ethical assessment of the TeGenero TGN1412 trial.

  Emanuel EJ, Miller FG. Emanuel EJ, et al. Am J Bioeth. 2007 Feb;7(2):76-81. doi: 10.1080/15265160601111800. Am J Bioeth. 2007. PMID: 17366206 Review.
• Evaluation of research design by research ethics committees: misleading reassurance and the need for substantive reforms.

  Mann H. Mann H. Am J Bioeth. 2007 Feb;7(2):84-6. doi: 10.1080/15265160601111859. Am J Bioeth. 2007. PMID: 17366208 No abstract available.
• An update on TGN1412.

  Bhogal N, Combes R. Bhogal N, et al. Altern Lab Anim. 2006 Jun;34(3):351-6. doi: 10.1177/026119290603400301. Altern Lab Anim. 2006. PMID: 16831066
• TGN1412: scrutinizing preclinical trials of antibody-based medicines.

  Hansen S, Leslie RG. Hansen S, et al. Nature. 2006 May 18;441(7091):282. doi: 10.1038/441282a. Nature. 2006. PMID: 16710395 No abstract available.
• First-in-Man (FIM) clinical trials post-TeGenero: a review of the impact of the TeGenero trial on the design, conduct, and ethics of FIM trials.

  Nada A, Somberg J. Nada A, et al. Am J Ther. 2007 Nov-Dec;14(6):594-604. doi: 10.1097/MJT.0b013e31813737dd. Am J Ther. 2007. PMID: 18090886 Review.